Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
Trial Parameters
Brief Summary
The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus. Effects of Tirzepatide on the occurrence and development of cognitive impairment in diabetic patients and its associated pattern of changes in brain neural network characteristics.
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes was diagnosed according to World Health Organization(WHO) classification or other locally applicable diagnostic criteria. * Received stable metformin with or without sulfonylureas at least 2 months prior to visit 1 and between visits 1 and 3 (metformin ≥ 1000 mg/ day and does not exceed the maximum dose specified in the nationally approved guidelines;Sulfonylureas should be at least half of the maximum dose as stated in the national approved instructions). * No insulin treatment (except for gestational diabetes or short-term use in acute Settings \[duration ≤14 days\]). * At visit 1, HbA1c ≥ 7.5% and ≤ 11.0% was determined according to the central laboratory. * Body mass index (BMI) ≥ 23 kg/m2. Exclusion Criteria: * Type 1 Diabetes Mellitus (T1DM) * Had chronic or acute pancreatitis at any time prior to visit 1. * A history of proliferative diabetic retinopathy or diabetic macular degeneration or non-proliferative diabetic retinopathy requiring acu